{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that standard deviation could not be calculated for a single participant.","groupId":"OG000","spread":"NA","value":"-0.0"}]}],"title":"Day 1 (Cycle 2)"},{"categories":[{"measurements":[{"comment":"NA indicates that standard deviation could not be calculated for a single participant.","groupId":"OG000","spread":"NA","value":"0.3"}]}],"title":"Day 1 (Cycle 3)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 0.06 mg/kg"}],"paramType":"MEAN","populationDescription":"Part 1 Population. NA indicates that standard deviation could not be calculated for a single participant.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 (Cycle 2 and 3)","title":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg","type":"PRIMARY","unitOfMeasure":"Grams per day"}